Drug intelligence / Profile preview

NCO-48 fumarate

Development stage: Unknown
Lead developer: Nucorion Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

NCO-48 fumarate is an orally administered small molecule prodrug of tenofovir being developed by Nucorion Pharmaceuticals for the treatment of chronic hepatitis B virus (HBV) infection. As a nucleotide analog, it is metabolized into its active form, tenofovir, which acts by inhibiting the HBV reverse transcriptase enzyme, thereby blocking viral DNA synthesis and replication. In clinical evaluations, NCO-48 fumarate has been studied in Phase 1 trials to assess its safety, pharmacokinetics, and antiviral activity in treatment-naive adults, comparing its efficacy and safety profile to tenofovir alafenamide (TAF).

Targets

HBV Pol (Hepatitis B virus polymerase)

Beyond the preview

Go deeper on NCO-48 fumarate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NCO-48 fumarate.

Explore the full profile